|
40 Companies |
|
36 Products |
|
36 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
262 News |
|
| «123456» |
- Rupex (rupatadine) / Incepta Pharma, Medexus
Enrollment closed: PAFCUTIII: Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria (clinicaltrials.gov) - Jul 3, 2013
P2, N=24, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting
- ||||||| Xolair (omalizumab) / Roche, Novartis
Trial completion: A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists (clinicaltrials.gov) - Jun 30, 2013
P3, N=336, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- gevokizumab (S 78989) / Novartis
New P2 trial: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum (clinicaltrials.gov) - Jun 18, 2013
P2, N=8, Active, not recruiting, Sponsor: XOMA (US) LLC
- ||||||| Trial completion: Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks (clinicaltrials.gov) - Jun 6, 2013
P3, N=75, Completed, Sponsor: Pharming Technologies B.V.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Berinert (C1 esterase inhibitor (human) IV) / CSL Behring
Enrollment open, P4 data: Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert (clinicaltrials.gov) - May 11, 2013
P4, N=48, Recruiting, Sponsor: CSL Behring
Active, not recruiting --> Completed Ongoing --> Recruiting
- Enrollment closed: Protocol For The Quantitation Of Pain In The Diagnosis Of Polymyalgia Rheumatica (clinicaltrials.gov) - May 6, 2013
P=N/A, N=150, Active, not recruiting, Sponsor: Lahey Clinic
Ongoing --> Recruiting Recruiting --> Active, not recruiting
- Trial initiation date: SOS AOH: A Call Center During HAE Attacks (SOS HAE) (clinicaltrials.gov) - Apr 29, 2013
P4, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting Initiation date: Sep 2012 --> Mar 2013
- Enrollment open: SOS AOH: A Call Center During HAE Attacks (SOS HAE) (clinicaltrials.gov) - Apr 29, 2013
P4, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Initiation date: Sep 2012 --> Mar 2013 Not yet recruiting --> Recruiting
- Orencia (abatacept) / BMS
Enrollment closed: Study to Evaluate The Safety and Efficacy of Abatacept in Subjects With Chronic Urticaria Who Have Had an Inadequate Response to Anti-histamine Therapy (clinicaltrials.gov) - Apr 9, 2013
P1/2, N=5, Active, not recruiting, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Berinert (C1 esterase inhibitor (human) IV) / CSL Behring, Haegarda (C1 esterase inhibitor subcutaneous [human]) / CSL Behring
Trial completion: A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor (clinicaltrials.gov) - Apr 3, 2013
P1, N=16, Completed, Sponsor: CSL Behring
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || prednisone delayed-release tablet / Generic mfg.
New P3 trial: A Study Assessing the Efficacy and Safety of Lodotra (clinicaltrials.gov) - Mar 27, 2013
P3, N=62, Terminated, Sponsor: Mundipharma Research Limited
- Xolair (omalizumab) / Roche, Novartis
New P2/3 trial: Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients (clinicaltrials.gov) - Feb 28, 2013
P2/3, N=30, Completed, Sponsor: University Hospital Inselspital, Berne
- | Enrollment change: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema (clinicaltrials.gov) - Feb 20, 2013
P2/3, N=14, Completed, Sponsor: Pharming Technologies B.V.
Active, not recruiting --> Completed N=30 --> 14
- Enrollment open: UCT-V: Validation of an Urticaria Control Test (clinicaltrials.gov) - Feb 13, 2013
P=N/A, N=100, Recruiting, Sponsor: Charite University, Berlin, Germany
N=30 --> 14 Not yet recruiting --> Recruiting
- ||| esomeprazole / Generic mfg.
Enrollment open: Drug Utilization and Safety Events Among Children Using Esomeprazole, Other Proton Pump Inhibitors or H2-receptor Antagonists (clinicaltrials.gov) - Jan 29, 2013
P=N/A, N=1500, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Berinert (C1 esterase inhibitor (human) IV) / CSL Behring, Haegarda (C1 esterase inhibitor subcutaneous [human]) / CSL Behring
New P1 trial: A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor (clinicaltrials.gov) - Jan 2, 2013
P1, N=16, Completed, Sponsor: CSL Behring
- hydroxychloroquine / Generic mfg.
Trial withdrawal: Hydroxychloroquine Efficacy in Chronic Urticaria (clinicaltrials.gov) - Dec 30, 2012
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
Not yet recruiting --> Recruiting Not yet recruiting --> Withdrawn
- hydroxychloroquine / Generic mfg.
Enrollment change: Hydroxychloroquine Efficacy in Chronic Urticaria (clinicaltrials.gov) - Dec 30, 2012
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
Not yet recruiting --> Withdrawn N=75 --> 0
- Firazyr (icatibant) / Takeda
Trial termination: Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema (clinicaltrials.gov) - Dec 17, 2012
P1, N=13, Terminated, Sponsor: Vanderbilt University
N=75 --> 0 Recruiting --> Terminated; This study was stopped to allow initiation of a mult-center study
- Firazyr (icatibant) / Takeda
Enrollment change: Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema (clinicaltrials.gov) - Dec 17, 2012
P1, N=13, Terminated, Sponsor: Vanderbilt University
Recruiting --> Terminated; This study was stopped to allow initiation of a mult-center study N=24 --> 13
- | azathioprine / Generic mfg.
Enrollment closed: CHUSPAN2: Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) (clinicaltrials.gov) - Dec 9, 2012
P3, N=114, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
N=24 --> 13 Recruiting --> Active, not recruiting
- ||||||| Xolair (omalizumab) / Roche, Novartis
Trial completion: A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) (clinicaltrials.gov) - Dec 3, 2012
P3, N=323, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial withdrawal: C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation (clinicaltrials.gov) - Nov 28, 2012
P4, N=0, Withdrawn, Sponsor: Penn State University
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Enrollment change: C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation (clinicaltrials.gov) - Nov 28, 2012
P4, N=0, Withdrawn, Sponsor: Penn State University
Not yet recruiting --> Withdrawn N=12 --> 0
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion: Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease (clinicaltrials.gov) - Nov 14, 2012
P3, N=196, Completed, Sponsor: University of California, San Diego
N=12 --> 0 Recruiting --> Completed
- || New P3 trial: Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria (clinicaltrials.gov) - Oct 25, 2012
P3, N=100, Not yet recruiting, Sponsor: Chang Gung Memorial Hospital
- Actemra IV (tocilizumab) / Roche, JW Pharma
New P2 trial: TENOR: Tocilizumab Effect iN pOlymyalgia Rheumatica (clinicaltrials.gov) - Oct 23, 2012
P2, N=20, Recruiting, Sponsor: University Hospital, Brest
- Xolair (omalizumab) / Roche, Novartis
New P2 trial: Efficacy and Safety Study of Omalizumab (Xolair (clinicaltrials.gov) - Oct 23, 2012
P2, N=20, Active, not recruiting, Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
- Orencia (abatacept) / BMS
Clinical: A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=30, Recruiting, Sponsor: New York University School of Medicine
- | aspirin / Generic mfg.
Trial completion: Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease (clinicaltrials.gov) - Sep 18, 2012
P4, N=45, Completed, Sponsor: Green Cross Corporation
Recruiting --> Completed Recruiting --> Completed
- | New P4 trial: SOS AOH: A Call Center During HAE Attacks (SOS HAE) (clinicaltrials.gov) - Sep 4, 2012
P4, N=200, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- levocetirizine / Generic mfg.
Trial termination: The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=11, Terminated, Sponsor: Wake Forest School of Medicine
Recruiting --> Completed Recruiting --> Terminated; Mediators of interest were not consistently detectable with the analytical methods employed.
- levocetirizine / Generic mfg.
Enrollment change: The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=11, Terminated, Sponsor: Wake Forest School of Medicine
Recruiting --> Terminated; Mediators of interest were not consistently detectable with the analytical methods employed. N=20 --> 11
- Natrecor (nesiritide) / J&J, Januvia (sitagliptin) / Merck (MSD)
Biomarker, Trial initiation date: Pharmacogenetics of Ace Inhibitor-Associated Angioedema (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=64, Recruiting, Sponsor: Vanderbilt University
N=20 --> 11 Initiation date: Aug 2011 --> Nov 2011
- Natrecor (nesiritide) / J&J, Januvia (sitagliptin) / Merck (MSD)
Biomarker, Enrollment open: Pharmacogenetics of Ace Inhibitor-Associated Angioedema (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=64, Recruiting, Sponsor: Vanderbilt University
Initiation date: Aug 2011 --> Nov 2011 Not yet recruiting --> Recruiting
- ||||| Xolair (omalizumab) / Roche, Novartis
Enrollment change: A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1) (clinicaltrials.gov) - Jul 23, 2012
P3, N=323, Completed, Sponsor: Genentech
Not yet recruiting --> Recruiting N=16 --> 323
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis (clinicaltrials.gov) - Jul 5, 2012
P3, N=69, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=16 --> 323 Active, not recruiting --> Completed
- Enrollment change: UCT-D: Development of an Urticaria Control Test (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=300, Recruiting, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed N=100 --> 300
- Clinical: UCT-D: Development of an Urticaria Control Test (clinicaltrials.gov) - May 30, 2012
P=N/A, N=300, Recruiting, Sponsor: Charite University, Berlin, Germany
- || bilastine / Generic mfg.
Trial completion: BUCUM: Bilastine Updosing - Characterization of Underlying Mechanisms (clinicaltrials.gov) - May 29, 2012
P2/3, N=20, Completed, Sponsor: Charite University, Berlin, Germany
N=100 --> 300 Active, not recruiting --> Completed
- Ilaris (canakinumab) / Novartis
Trial completion: ILUVIT: Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses (clinicaltrials.gov) - May 29, 2012
P2, N=10, Completed, Sponsor: Charite University, Berlin, Germany
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Rupex (rupatadine) / Incepta Pharma, Medexus
New P2 trial: PAFCUTIII: Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria (clinicaltrials.gov) - May 23, 2012
P2, N=24, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
- | Xolair (omalizumab) / Roche, Novartis
New P2 trial: Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment (clinicaltrials.gov) - May 14, 2012
P2, N=38, Completed, Sponsor: Novartis Pharmaceuticals
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P3 trial: Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease (clinicaltrials.gov) - May 9, 2012
P3, N=100, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
- Clinical: Behçet's Disease and Eosinophil Cationic Protein (clinicaltrials.gov) - Apr 23, 2012
P=N/A, N=47, Completed, Sponsor: Cukurova University
- | Firazyr (icatibant) / Takeda
Enrollment open: Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE (clinicaltrials.gov) - Apr 17, 2012
P4, N=30, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Xolair (omalizumab) / Roche, Novartis
New P2 trial: CUTEX: Cold Urticaria Treatment With Xolair (clinicaltrials.gov) - Apr 17, 2012
P2, N=60, Recruiting, Sponsor: Charite University, Berlin, Germany
- Enrollment change: Association of Thyroid Autoimmunity and Chronic Urticaria (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=155, Completed, Sponsor: Far Eastern Memorial Hospital
Not yet recruiting --> Recruiting N=100 --> 155
- Trial completion: Association of Thyroid Autoimmunity and Chronic Urticaria (clinicaltrials.gov) - Mar 25, 2012
P=N/A, N=155, Completed, Sponsor: Far Eastern Memorial Hospital
N=100 --> 155 Recruiting --> Completed
- Trial completion: Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis (clinicaltrials.gov) - Mar 22, 2012
P=N/A, N=26, Completed, Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
Recruiting --> Completed Not yet recruiting --> Completed